Elan Corporation PLC (ELN.I)
9.52EUR
24 May 2013
€0.05 (+0.58%)
€9.52
€9.59
€9.65
€9.48
335,339
1,839,372
€12.01
€6.83
ELN.I
About
Overall
| Beta: | 0.52 |
| Market Cap (Mil.): | €4,863.21 |
| Shares Outstanding (Mil.): | 510.34 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| ELN.I | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 46.63 | 34.30 |
| EPS (TTM): | -0.48 | -- | -- |
| ROI: | -27.52 | 1.55 | 18.43 |
| ROE: | -52.59 | 2.77 | 19.30 |
Elan prices $850 million senior notes
DUBLIN, May 24 - Irish drug firm Elan will issue $850 million worth of senior notes at par, the company said on Friday.
Elan rejects Royalty's $6.4 billion raised offer
DUBLIN - Elan rejected Royalty Pharma's increased $6.4 billion bid on Thursday, shortly after the U.S. firm cut the acceptance bar for its latest offer to 50 percent plus one share.
UPDATE 2-Elan rejects Royalty's $6.4 bln raised offer
* Elan says new bid continues to grossly undervalue company
BRIEF-Royalty Pharma updates terms of Elan offer
LONDON, May 23 - Royalty Pharma : * Royalty Pharma reduces acceptance condition to 50% plus one share * Under the terms of the increased offer, Royalty Pharma is offering to acquire Elan for $12.50 per share in cash * Increased offer represents a value of $4.6 billion for Elan's Tysabri royalty * Offer is fully financed and is not conditional on due
Royalty raises Elan bid, issues ultimatum to shareholders
DUBLIN/NEW YORK - Royalty Pharma raised its hostile bid for Elan to $12.50 per share and threatened to withdraw the bid if Elan shareholders approve a series of defensive transactions announced by the Irish drug firm.
UPDATE 3-Royalty raises Elan bid, issues ultimatum to shareholders
* Royalty will withdraw bid if shareholders back Elan deals
Elan strikes more deals, agrees second share buyback
* Elan buys rare drug specialist AOP Orphan for 263 mln eur
Elan says Royalty wanted to take it private before Tysabri deal
DUBLIN, May 15 - Royalty Pharma last year urged Elan to hold off on a multi-billion dollar drug deal until it had taken the Irish drugmaker private to boost the compensation the firms' executives would receive, Elan said on Wednesday.
Elan's $1 billion drug royalty deal aids bid defense
DUBLIN - Irish drugmaker Elan Corporation has agreed a $1 billion royalties deal that could soothe concerns about its potentially risky acquisition strategy and fend off a takeover bid from Royalty Pharma.
Elan CEO says shareholders unmoved by Royalty bid
DUBLIN - Elan's chief executive said he has not spoken to one shareholder who views Royalty Pharma's bid for the company as credible and that it had nothing to do with Monday's deal with fellow drugmaker Theravance.
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Plunkett Research, Ltd.
|
$99.00
|
|
Provider: Plunkett Research, Ltd.
|
$99.00
|
|
Provider: Plunkett Research, Ltd.
|
$99.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
